The AI-driven wearable sensor demonstrates high accuracy in reducing nighttime scratching for atopic dermatitis, improving patient outcomes and sleep quality.
For children with atopic dermatitis, early childhood stressful life events are associated with an increased risk for disease activity.
We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...
Cold weather, dry air, an overactive immune system or our modern lifestyle. The causes may vary, but an increasing number of ...
Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...
The production of isocyanate compounds from the environment may explain the increasing prevalence of atopic dermatitis, according to a speaker at Masters of Pediatric Dermatology. “We understand that ...
Saudi Gazette on MSN1d
Oilatum tackles rise in Eczema and Dry Skin in Saudi ArabiaAs eczema and dry skin continue to rise in Saudi Arabia, driven by the Kingdom’s harsh climate and increased environmental stressors, Oilatum has launched an expanded product line to provide effective ...
Q4 2024 Earnings Call Transcript February 10, 2025 Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and ...
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...
Greetings and welcome to the Incyte fourth-quarter 2024 and full-year financial and corporate update conference call webcast. (Operator Instructions) As a reminder, this conference is being recorded.
Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...
Q4 2024 total revenues reached $1.2 billion, with $1 billion in product revenues. Jakafi's Q4 net revenue increased 11% year-over-year to $773 million, while Opzelura's Q4 revenue grew 48% to $162 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results